Roche Inks ‘The Largest Obesity Deal To Date’ With Zealand Pharma At $5.3 Billion Investor’s Business Daily
Category: GLP-1 News
Roche Targets Weight-Loss Drug Market Dominated by Novo Nordisk, Eli Lilly – Investopedia
Roche Targets Weight-Loss Drug Market Dominated by Novo Nordisk, Eli Lilly Investopedia
Roche Further Boosts Obesity Pipeline With Zealand Pharma Deal Worth $5.3 Billion For Weight Loss Drugs – Benzinga
Roche Further Boosts Obesity Pipeline With Zealand Pharma Deal Worth $5.3 Billion For Weight Loss Drugs Benzinga
What are the other health benefits weight-loss drugs may offer? – TODAY
What are the other health benefits weight-loss drugs may offer? TODAY
How weight-loss drugs could help treat addiction, arthritis, more – TODAY
How weight-loss drugs could help treat addiction, arthritis, more TODAY
Novo Nordisk, Lilly Stocks Are Falling. A Rival Weight-Loss Drug Is on the Way. – Barron’s
Novo Nordisk, Lilly Stocks Are Falling. A Rival Weight-Loss Drug Is on the Way. Barron’s
How the New Weight Loss Medications Change Our Relationship With Food – Yale School of Medicine
How the New Weight Loss Medications Change Our Relationship With Food Yale School of Medicine
How the New Weight Loss Medications Change Our Relationship With Food – Yale School of Medicine
How the New Weight Loss Medications Change Our Relationship With Food Yale School of Medicine
More claimants interested in weight-loss drugs; few are covered in comp – Business Insurance
More claimants interested in weight-loss drugs; few are covered in comp Business Insurance
Ekta Kapoor wonders about the best weight loss solution: ‘Ozempic, Mounjaro or anti-inflammatory diet’ – The Indian Express
Ekta Kapoor wonders about the best weight loss solution: ‘Ozempic, Mounjaro or anti-inflammatory diet’ The Indian Express